Cargando…

In Vitro Characterization of (177)Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer

Carcinoembryonic antigen (CEA) is an antigen that is highly expressed in colorectal cancers and widely used as a tumor marker. (131)I and (90)Y-radiolabeled anti-CEA monoclonal antibodies (mAbs) have previously been assessed for radioimmunotherapy in early clinical trials with promising results. Mor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohajershojai, Tabassom, Jha, Preeti, Boström, Anna, Frejd, Fredrik Y., Yazaki, Paul J., Nestor, Marika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010075/ https://www.ncbi.nlm.nih.gov/pubmed/35433442 http://dx.doi.org/10.3389/fonc.2022.849338

Ejemplares similares

Enhanced Therapeutic Effects of (177)Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts
por: Mohajershojai, Tabassom, et al.
Publicado: (2023)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

In vitro characterisation of [(177)Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
por: Hull, Ashleigh, et al.
Publicado: (2023)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Radioligand Therapy with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Anti-CD45 Radioimmunotherapy with (90)Y but Not (177)Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model
por: Orozco, Johnnie J., et al.
Publicado: (2014)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

An approach for conjugation of (177)Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
por: Thakral, Parul, et al.
Publicado: (2014)

p53-Mediated Radiosensitization of (177)Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Lundsten, Sara, et al.
Publicado: (2021)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

Biodistribution and post-therapy dosimetric analysis of [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results
por: Khawar, Ambreen, et al.
Publicado: (2019)

Radiation exposure assessment of nuclear medicine staff administering [(177)Lu]Lu-DOTA-TATE with active and passive dosimetry
por: Riveira-Martin, Mercedes, et al.
Publicado: (2023)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Optimization of (177)Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
por: Cankaya, Aylin, et al.
Publicado: (2023)

Labelling of (90)Y- and (177)Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis
por: Iori, Michele, et al.
Publicado: (2017)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lo5phfu364fvot2r2ke2h6f4br